admin – Page 2896 – Get News Story

Growth Hormone Deficiency Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Novo Nordisk, Ascendis Pharma, Double Point Ventures (Lumos Pharma), SCOHIA PHARMA

The Key Growth Hormone Deficiency Companies in the market include – Novo Nordisk, Ascendis Pharma, Double Point Ventures (Lumos Pharma), SCOHIA PHARMA, and others.

The Growth Hormone Deficiency market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Growth Hormone Deficiency market dynamics.

DelveInsight’s “Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Growth Hormone Deficiency, historical and forecasted epidemiology as well as the Growth Hormone Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Growth Hormone Deficiency market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Growth Hormone Deficiency Market Forecast

Some of the key facts of the Growth Hormone Deficiency Market Report:

In 2023, the Growth Hormone Deficiency market across the 7MM was estimated to be worth around USD 1.4 billion. Between 2025 and 2034, the market is expected to expand at a compound annual growth rate (CAGR) of 5.7%.
In 2023, the Growth Hormone Deficiency market in the United States was valued at around USD 873.4 million and is expected to grow further with the introduction of upcoming therapies.
In 2023, the combined market size of the EU4 and the UK was estimated at around USD 370.2 million, accounting for nearly 27% of the total revenue across the 7MM.
In 2023, Germany led the Growth Hormone Deficiency market within the EU4 and the UK, with revenue of approximately USD 96.5 million. The UK came next with around USD 86.2 million, followed by France at roughly USD 82.0 million.
In 2023, Japan’s total market size for Growth Hormone Deficiency was estimated at around USD 137.0 million, with expectations of growth throughout the forecast period (2025–2034).
Projections indicate that LUM-201 is anticipated to generate around USD 131.1 million in revenue across the 7MM by 2034.
DelveInsight estimates that in 2023, there were around 206,000 total prevalent cases of Growth Hormone Deficiency across the 7MM, with approximately 165,000 of those being diagnosed. Among the diagnosed cases, the United States accounted for about 42.5%, while the combined total for EU4 and the UK was close to 41.7%, and Japan comprised 15.8%.
Currently, the Growth Hormone Deficiency treatment landscape includes therapies such as somatotropin, SOGROYA, SKYTROFA/TRANSCON hGH, NGENLA, GROWJECT, and others available in the market.
According to DelveInsight, the prevalence of Growth Hormone Deficiency in the 7MM was approximately 206,000 in 2023. This figure is expected to rise at a CAGR of 0.4%, reaching greater levels by 2034.
DelveInsight estimates that approximately 165,000 diagnosed cases of Growth Hormone Deficiency were reported across the 7MM in 2023. This number is anticipated to grow at a CAGR of 0.4% throughout the forecast period (2020–2034).
In 2023, the United States represented roughly 51% of the diagnosed prevalent pediatric Growth Hormone Deficiency cases across the 7MM, while EU4 and the UK contributed close to 36%, and Japan accounted for about 13%.
In 2023, the United States made up about 40% of the diagnosed prevalent adult Growth Hormone Deficiency cases in the 7MM, while EU4 and the UK comprised nearly 43%, and Japan contributed approximately 17%.
In 2023, the United States reported around 49,000 cases of Growth Hormone Deficiency in males and 21,000 in females, with these figures projected to increase by 2034.
In 2023, approximately 42,000 male and 26,000 female cases of Growth Hormone Deficiency were reported in the EU4 and the UK, with these numbers anticipated to grow by 2034.
Key Growth Hormone Deficiency Companies: Novo Nordisk, Ascendis Pharma, Double Point Ventures (Lumos Pharma), SCOHIA PHARMA, and others
Key Growth Hormone Deficiency Therapies: SOGROYA (somapacitan-beco), SKYTROFA/TRANSCON hGH (lonapegsomatropin-tcgd), LUM-201 (ibutamoren), SCO-240, and others
The Growth Hormone Deficiency market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Growth Hormone Deficiency pipeline products will significantly revolutionize the Growth Hormone Deficiency market dynamics.

Growth Hormone Deficiency Overview

Growth Hormone Deficiency (GHD) is a medical condition in which the body doesn’t produce enough growth hormone, a key hormone responsible for growth, cell repair, and metabolism. It can occur in both children and adults. In children, GHD leads to slowed growth and short stature, while in adults, it may cause fatigue, reduced muscle mass, increased fat, and poor bone density. Causes can include genetic disorders, brain injuries, or tumors. Treatment typically involves daily injections of synthetic growth hormone to restore normal growth and metabolic function.

Request a sample for the Growth Hormone Deficiency Market Report:

https://www.delveinsight.com/report-store/growth-hormone-deficiency-ghd-market

Growth Hormone Deficiency Epidemiology

The Growth Hormone Deficiency epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Growth Hormone Deficiency Epidemiology Segmentation:

The Growth Hormone Deficiency market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Growth Hormone Deficiency
Prevalent Cases of Growth Hormone Deficiency by severity
Gender-specific Prevalence of Growth Hormone Deficiency
Diagnosed Cases of Episodic and Chronic Growth Hormone Deficiency

Download the report to understand which factors are driving Growth Hormone Deficiency epidemiology trends @ Growth Hormone Deficiency Epidemiological Insights

Growth Hormone Deficiency Market

The dynamics of the Growth Hormone Deficiency market are anticipated to change in the coming years owing to the expected launch of emerging therapies, and others during the forecast period 2020-2034.

Growth Hormone Deficiency Therapies and Companies

Novo Nordisk: SOGROYA (somapacitan-beco)
Ascendis Pharma: SKYTROFA/TRANSCON hGH (lonapegsomatropin-tcgd)
Double Point Ventures (Lumos Pharma): LUM-201 (ibutamoren)
SCOHIA PHARMA: SCO-240

To know more about Growth Hormone Deficiency treatment, visit @ Growth Hormone Deficiency Medications

Growth Hormone Deficiency Market Strengths

Various approved therapies are available in the market for this condition which can help in successfully treating PGHD.
The emerging pipeline has some very potential treatments for PGHD.

Growth Hormone Deficiency Market Opportunities

Since the emerging and approved treatments mainly comprise of long-acting hGH, this is a major opportunity for companies to develop novel drugs with innovative mechanism of action for PGHD which will give them an edge in the current market.

Scope of the Growth Hormone Deficiency Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Growth Hormone Deficiency Companies: Novo Nordisk, Ascendis Pharma, Double Point Ventures (Lumos Pharma), SCOHIA PHARMA, and others
Key Growth Hormone Deficiency Therapies: SOGROYA (somapacitan-beco), SKYTROFA/TRANSCON hGH (lonapegsomatropin-tcgd), LUM-201 (ibutamoren), SCO-240, and others
Therapeutic Assessment: Growth Hormone Deficiency current marketed and Growth Hormone Deficiency emerging therapies
Growth Hormone Deficiency Market Dynamics: Growth Hormone Deficiency market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Growth Hormone Deficiency Unmet Needs, KOL’s views, Analyst’s views, Growth Hormone Deficiency Market Access and Reimbursement

Discover more about therapies set to grab major Growth Hormone Deficiency market share @ Growth Hormone Deficiency Treatment Landscape

Table of Contents

1. Growth Hormone Deficiency Market Report Introduction

2. Executive Summary for Growth Hormone Deficiency

3. SWOT analysis of Growth Hormone Deficiency

4. Growth Hormone Deficiency Patient Share (%) Overview at a Glance

5. Growth Hormone Deficiency Market Overview at a Glance

6. Growth Hormone Deficiency Disease Background and Overview

7. Growth Hormone Deficiency Epidemiology and Patient Population

8. Country-Specific Patient Population of Growth Hormone Deficiency

9. Growth Hormone Deficiency Current Treatment and Medical Practices

10. Growth Hormone Deficiency Unmet Needs

11. Growth Hormone Deficiency Emerging Therapies

12. Growth Hormone Deficiency Market Outlook

13. Country-Wise Growth Hormone Deficiency Market Analysis (2020–2034)

14. Growth Hormone Deficiency Market Access and Reimbursement of Therapies

15. Growth Hormone Deficiency Market drivers

16. Growth Hormone Deficiency Market barriers

17. Growth Hormone Deficiency Appendix

18. Growth Hormone Deficiency Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Garurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Growth Hormone Deficiency Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Novo Nordisk, Ascendis Pharma, Double Point Ventures (Lumos Pharma), SCOHIA PHARMA

Diffuse Large B-cell Lymphoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Xynomic Pharma, Hanmi Pharma, S IMV Inc. Seagen

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Diffuse Large B-cell Lymphoma pipeline constitutes 70+ key companies continuously working towards developing 75+ Diffuse Large B-cell Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Diffuse Large B-cell Lymphoma Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diffuse Large B-cell Lymphoma Market.

The Diffuse Large B-cell Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Diffuse Large B-cell Lymphoma Pipeline Report:

Companies across the globe are diligently working toward developing novel Diffuse Large B-cell Lymphoma treatment therapies with a considerable amount of success over the years.
Diffuse Large B-cell Lymphoma companies working in the treatment market are Ubix Therapeutics, Otsuka Pharmaceutical Co., Ltd, Biomea Fusion Inc, Autolus Limited, Xynomic Pharmaceuticals, Inc., Hanmi Pharmaceutical, S IMV Inc. Seagen Inc., Zai Lab, Genentech, and others, are developing therapies for the Diffuse Large B-cell Lymphoma treatment

Emerging Diffuse Large B-cell Lymphoma therapies in the different phases of clinical trials are- UBX-303, OPB-111077, BMF-219, AUTO3, Abexinostat, Poseltinib, Maveropepimut, Brentuximabvedotin, Odronextamab, Mosunetuzumab, and others are expected to have a significant impact on the Diffuse Large B-cell Lymphoma market in the coming years.
In May 2025, Merck & Co (MSD)’s antibody-drug conjugate, zilovertamab vedotin, developed for the treatment of diffuse large B-cell lymphoma (DLBCL), has shown encouraging results in a Phase II/III clinical trial, positioning the company to potentially rival ADC Therapeutics’ already approved therapy.
In March 2025, The FDA has granted Fast Track designation to azer-cel, an allogeneic, off-the-shelf CD19-targeted CAR T-cell therapy, for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Currently, a Phase 1b clinical trial (NCT03666000) is ongoing to assess azer-cel in individuals with relapsed or refractory non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia. This multicenter, open-label, nonrandomized trial involves dose escalation and expansion to evaluate the safety and clinical efficacy of the therapy in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma.
In February 2025, Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has launched waveLINE-010, a pivotal Phase 3 clinical trial assessing zilovertamab vedotin in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) against rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for previously untreated diffuse large B-cell lymphoma (DLBCL). Zilovertamab vedotin is Merck’s investigational antibody-drug conjugate (ADC) designed to target receptor tyrosine kinase-like orphan receptor 1 (ROR1).
In December 2024, Genmab A/S (Nasdaq: GMAB) has released new long-term findings from two ongoing clinical trials assessing epcoritamab, a subcutaneously administered T-cell engaging bispecific antibody, in adult patients with diffuse large B-cell lymphoma (DLBCL). Data from Arm 1 of the Phase 1b/2 EPCORE® NHL-2 trial (NCT04663347) showed that fixed-duration epcoritamab combined with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) achieved a 100% overall response rate (ORR) and an 87% complete response (CR) rate in high-risk, previously untreated DLBCL patients (n=46).
In November 2024, Novotech, a leading global full-service clinical Contract Research Organization (CRO), continues to strengthen its role in oncology research by providing new insights into the global clinical trial landscape for Diffuse Large B-Cell Lymphoma (DLBCL). The company, which collaborates with biotech firms to advance novel therapeutics across all phases, highlights the promising progress of Phase III trials for Mosunetuzumab and Selinexor, particularly in patients with relapsed or refractory DLBCL.
In June 2024, Pfizer Inc. (NYSE: PFE) reported detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS® (brentuximab vedotin) combined with lenalidomide and rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study indicated that this combination reduced the risk of death by 37% compared to a placebo combined with lenalidomide and rituximab (HR 0.63 [95% CI: 0.445-0.891], p=0.0085). The OS benefit was consistent across all levels of CD30 expression. These results will be presented as a late-breaking abstract (LBA7005) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, alongside four-year results from the Phase 3 HD21 trial in advanced classical Hodgkin lymphoma (cHL) (LBA7000).
In April 2024, Roche has disclosed findings from the Phase III STARGLO trial demonstrating that its treatment Columvi (glofitamab), in combination with gemcitabine and oxaliplatin (GemOx), enhanced overall survival (OS) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This multicenter, open-label, randomized study evaluated the safety and effectiveness of Columvi plus GemOx versus MabThera/Rituxan (rituximab) combined with GemOx.
In March 2024, GenFleet Therapeutics has entered into a clinical trial collaboration and supply agreement with BeiGene Switzerland to initiate a Phase Ib/II clinical trial combining GFH009 and BRUKINSA (zanubrutinib) for the treatment of diffuse large B cell lymphoma (DLBCL). GFH009 is a cyclin-dependent kinase 9 (CDK9) inhibitor developed by GenFleet, while BRUKINSA is a Bruton’s tyrosine kinase (BTK) inhibitor from BeiGene.

Diffuse Large B-cell Lymphoma Overview

Diffuse Large B-cell Lymphoma (DLBCL) is the most common and aggressive type of non-Hodgkin lymphoma, originating from abnormal B lymphocytes. It typically grows rapidly in lymph nodes but can also affect other organs. Symptoms may include swollen lymph nodes, fever, weight loss, and night sweats. DLBCL is considered treatable and potentially curable, especially when diagnosed early, with standard therapies like R-CHOP (a combination of chemotherapy and immunotherapy).

Get a Free Sample PDF Report to know more about Diffuse Large B-cell Lymphoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight

Emerging Diffuse Large B-cell Lymphoma Drugs Under Different Phases of Clinical Development Include:

UBX-303: Ubix Therapeutics
OPB-111077: Otsuka Pharmaceutical Co., Ltd
BMF-219: Biomea Fusion Inc
AUTO3: Autolus Limited
Abexinostat: Xynomic Pharmaceuticals, Inc.
Poseltinib: Hanmi Pharmaceutical
Maveropepimut: S IMV Inc.
Brentuximabvedotin: Seagen Inc.
Odronextamab: Zai Lab
Mosunetuzumab: Genentech

Diffuse Large B-cell Lymphoma Route of Administration

Diffuse Large B-cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Molecule Type

Diffuse Large B-cell Lymphoma Molecule Type

Diffuse Large B-cell Lymphoma Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Diffuse Large B-cell Lymphoma Pipeline Therapeutics Assessment

Diffuse Large B-cell Lymphoma Assessment by Product Type
Diffuse Large B-cell Lymphoma By Stage and Product Type
Diffuse Large B-cell Lymphoma Assessment by Route of Administration
Diffuse Large B-cell Lymphoma By Stage and Route of Administration
Diffuse Large B-cell Lymphoma Assessment by Molecule Type
Diffuse Large B-cell Lymphoma by Stage and Molecule Type

DelveInsight’s Diffuse Large B-cell Lymphoma Report covers around 75+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Diffuse Large B-cell Lymphoma product details are provided in the report. Download the Diffuse Large B-cell Lymphoma pipeline report to learn more about the emerging Diffuse Large B-cell Lymphoma therapies

Some of the key companies in the Diffuse Large B-cell Lymphoma Therapeutics Market include:

Key companies developing therapies for Diffuse Large B-cell Lymphoma are – AstraZeneca, Bristol-Myers Squibb, Seattle Genetics/Takeda, ADC Therapeutics, SymBio Pharmaceuticals, Denovo Biopharma, Merck, Amgen, TG Therapeutics, Bayer and others.

Diffuse Large B-cell Lymphoma Pipeline Analysis:

The Diffuse Large B-cell Lymphoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Diffuse Large B-cell Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diffuse Large B-cell Lymphoma Treatment.
Diffuse Large B-cell Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Diffuse Large B-cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diffuse Large B-cell Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Diffuse Large B-cell Lymphoma drugs and therapies

Diffuse Large B-cell Lymphoma Pipeline Market Drivers

Increasing Prevalence of DLBCL, increased research and development and CAR-T therapies are some of the important factors that are fueling the Diffuse Large B-cell Lymphoma Market.

Diffuse Large B-cell Lymphoma Pipeline Market Barriers

However, high cost of treatment, aggressive disease biology and geriatric vulnerability and other factors are creating obstacles in the Diffuse Large B-cell Lymphoma Market growth.

Scope of Diffuse Large B-cell Lymphoma Pipeline Drug Insight

Coverage: Global
Key Diffuse Large B-cell Lymphoma Companies: Ubix Therapeutics, Otsuka Pharmaceutical Co., Ltd, Biomea Fusion Inc, Autolus Limited, Xynomic Pharmaceuticals, Inc., Hanmi Pharmaceutical, S IMV Inc. Seagen Inc., Zai Lab, Genentech, and others
Key Diffuse Large B-cell Lymphoma Therapies: UBX-303, OPB-111077, BMF-219, AUTO3, Abexinostat, Poseltinib, Maveropepimut, Brentuximabvedotin, Odronextamab, Mosunetuzumab, and others
Diffuse Large B-cell Lymphoma Therapeutic Assessment: Diffuse Large B-cell Lymphoma current marketed and Diffuse Large B-cell Lymphoma emerging therapies
Diffuse Large B-cell Lymphoma Market Dynamics: Diffuse Large B-cell Lymphoma market drivers and Diffuse Large B-cell Lymphoma market barriers

Request for Sample PDF Report for Diffuse Large B-cell Lymphoma Pipeline Assessment and clinical trials

Table of Contents

1. Diffuse Large B-cell Lymphoma Report Introduction

2. Diffuse Large B-cell Lymphoma Executive Summary

3. Diffuse Large B-cell Lymphoma Overview

4. Diffuse Large B-cell Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. Diffuse Large B-cell Lymphoma Pipeline Therapeutics

6. Diffuse Large B-cell Lymphoma Late Stage Products (Phase II/III)

7. Diffuse Large B-cell Lymphoma Mid Stage Products (Phase II)

8. Diffuse Large B-cell Lymphoma Early Stage Products (Phase I)

9. Diffuse Large B-cell Lymphoma Preclinical Stage Products

10. Diffuse Large B-cell Lymphoma Therapeutics Assessment

11. Diffuse Large B-cell Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Diffuse Large B-cell Lymphoma Key Companies

14. Diffuse Large B-cell Lymphoma Key Products

15. Diffuse Large B-cell Lymphoma Unmet Needs

16 . Diffuse Large B-cell Lymphoma Market Drivers and Barriers

17. Diffuse Large B-cell Lymphoma Future Perspectives and Conclusion

18. Diffuse Large B-cell Lymphoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diffuse Large B-cell Lymphoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Xynomic Pharma, Hanmi Pharma, S IMV Inc. Seagen

smart Drives Forward in the Year of Enhancing Global Operation 7 New Global Markets and Expanded Product Offerings

June 25, 2025 – Hangzhou, China – As smart advances through 2025 – the year of enhancing global operation – the premium electric automotive brand continues to drive innovation across global markets through strategic partnerships and product excellence. In the first half of 2025, smart has made significant inroads into the global market landscape, successfully entering seven new markets across the MENA region and Latin America. The business footprint has now expanded to 38 countries and regions, with exceeding 580 stores worldwide.

In the first half of 2025, smart continued to expand its global footprint and make its entry into 7 new markets.
Significant R&D advancements in future products and technologies have been made, solidifying the company’s long-term value proposition and meeting diverse customer needs.
With the launch of “open your mind Experiences” global campaign, smart keeps sharpening its renewed brand image and forged collaborations with iconic brands and Intellectual Properties, including BRABUS, Sennheiser, TREK, Keith Haring globally and Disney’s Mickey & Friends and Peet’s Coffee in China.

公路上有许多车

描述已自动生成

In the first half of 2025, smart continued to expand its global footprint and make its entry into 7 new markets

The business footprint has now expanded to 38 countries and regions

With the launch of “open your mind Experience” global campaign, smart is sharpening its renewed brand image, and initating various crossover collaborations. In addition, the brand continues to enrich its product offerings, with plans to unveil more latest R&D technology and product results in the coming months.

Mr. Tong Xiangbei, Global CEO of smart

Mr. Tong Xiangbei, Global CEO of smart, said: “In the first half of 2025, smart has accelerated global expansion by entering new markets and expanding our product offerings with innovative models. Meanwhile, significant R&D advancements in future products and technologies have been made, solidifying the young global company’s long-term value proposition and enabling us to meet diverse customer needs worldwide.”

Sharpening the Brand Image through Inspirational Co-creation

During Auto Shanghai 2025, smart officially launched the “open your mind Experiences” global campaign, which was built around the “Power of Firsts” – the belief that first-time experiences create powerful emotional connections and unlock new possibilities. Embodying more first-time creative experiences, smart has forged collaborations with several iconic brands and Intellectual Properties throughout the first half of 2025.

The partnership with the Keith Haring Foundation aligns street art with smart’s urban mobility vision, debuting the smart #3 Keith Haring Art Car, with plans for a production version later this year. The collaboration with Disney in China enhances smart’s inspiration with imagination and fun. This marks smart’s second partnership with Mickey & Friends following the smart fortwo electric drive Disney edition from 11 years ago. smart and Peet’s Coffee co-created the #1 Crema Edition for the Chinese market which features distinctive black-gold coloring and exclusive interior elements.

男人的照片上写着字

描述已自动生成

Ms. Mandy Zhang, Global CMO of smart

Ms. Mandy Zhang, Global CMO of smart, said: “We actively bring the “open your mind” brand claim to life through innovative collaborations with iconic global brands and IPs. From high-performance upgrades with BRABUS and immersive audio experiences with Sennheiser to embedding Keith Haring’s iconic art in product designs, our partnerships span automotive, art, and lifestyle realms—including co-creations with TREK, Mickey & Friends, Peet’s Coffee, and many more. These partnerships embody our commitment to breaking boundaries and continuing sharpening our distinctive brand image across diverse cultures. As we grow our brand presence, we are working closely with partners across 38 countries and regions to deliver enhanced service experiences to our customers.”

Mindful Technology Advancements: Enhanced ADAS and Intelligent Cabin

smart continued to enhance its mindful technology offerings in the first half of 2025. The smart #5’s Navigation on smart Pilot (NSP) function has been activated in the Chinese mainland, providing enhanced driving assistance for local customers. Additionally, smart achieved the first implementation of AI-powered interactions in the smart #5, advancing its intelligent cabin experience.

Featuring these mindful technologies, the smart #5 continues its global rollout. The smart #5 BRABUS made its world premiere during the Milan Design Week in Italy, followed by successful launches in the European markets, Hong Kong China, and making its premiere in Malaysia, receiving positive feedback from global media and customers.

The smart #5 BRABUS made its world premiere during the Milan Design Week in Italy

As smart progresses through the year of enhancing global operation, the brand remains committed to delivering exceptional experiences for customers worldwide. Through continued market expansion, innovative partnerships, and product excellence, smart will keep inspiring customers to discover what happens when you open your mind to new possibilities.

Contact:

Sebastian Liu

sebastian.liu@smart.com

About smart

Since the birth of the brand in the 1990s, smart has always maintained the vision of exploring the best solutions for future urban mobility. In late 2019, Mercedes-Benz AG and Zhejiang Geely Holding Group officially established smart global joint venture.

From 2019 to 2024, after the comprehensive renewal of its brand, products, and business model, smart successfully achieved the strategic objectives set for its initial five-year phase. Adhering steadfastly to the “China-Europe, Dual Home” global development strategy, smart has transformed into a leading premium electric automotive brand. It now boasts an expanding product matrix and a global footprint spanning around 40 countries and regions. In 2025, smart aims to boost its global business operations.

Media Contact
Company Name: Smart
Contact Person: Sebastian Liu
Email: Send Email
Country: China
Website: media.smart.com

“By Force and Fear – A Stolen Homeland” Unveils a Haunting True Story of Survival, Courage, and the Fight for Freedom

Author and psychotherapist Anna Goodwin sheds light on a forgotten chapter of 20th-century history with her gripping new book, By Force and Fear: A Stolen Homeland. Drawing from the true stories passed down by her father, the book captures the terrifying upheaval of the Russian Revolution through the eyes of a 12-year-old boy who became a man overnight.

Set in Southern Russia near the Caspian Sea in 1918, the story begins as an army of a thousand Tatars thunders down the Caucasus Mountains, devastating peaceful German villages. In mere hours, young Chnals is forced to assume responsibility for his younger siblings, his childhood stripped away by violence and fear. What follows is a powerful and personal journey of flight, survival, faith, and the pursuit of liberty.

This historically grounded narrative explores the raw cost of freedom in a land torn by revolution and anarchy. With the Czar dethroned and communism on the rise, families like Chnals’s faced persecution, displacement, and death. Through running, hiding, crying, and moments of unexpected laughter, Chnals’s story reveals not just the pain of exile, but the hope that sustains those who dare to dream of a better life.

The book is also a poignant memoir. Inspired by her father’s haunting memories, Anna Goodwin reconnects with her family’s past, delving into the long-lasting effects of trauma and displacement, both on those who endure it and the generations that follow.

Reviewer J. Noyes writes, “Anna Unger-Goodwin does a masterful job of capturing her father and his family’s harrowing escape from Russia during the Revolution. Danger was ever-present and survival was never assured, even as acts of kindness aided their escape… A memorable and thought-provoking read.”

By Force and Fear: A Stolen Homeland is a powerful testament to the endurance of faith, the cost of silence, and the legacy of those who dared to resist tyranny.

The book is now available on Kindle and in paperback on Amazon and Barnes & Noble.

Get a powerful glimpse into By Force and Fear: A Stolen Homeland through its official book trailer. Feel the urgency, the emotion, and the hope that drives this unforgettable true story.

About the Author

Anna Goodwin grew up on a farm in rural Manitoba, Canada, the daughter of German-Russian immigrants whose lives were shaped by war, displacement, and resilience. She holds a Master of Science degree in Child and Family Psychotherapy from the University of Maryland. With a distinguished career spanning clinical practice and academia, Anna developed a large private psychotherapy practice in Montana and served as an assistant professor at two universities.

She has presented widely at national conferences, conducted workshops, and delivered keynote addresses, often focusing on trauma and post-traumatic stress issues deeply personal to her family’s history. Over half her clients dealt with PTSD, and through her clinical insight, she brings a profound psychological depth to her writing.

Now retired, Anna continues to write books that bridge history, memory, and healing. By Force and Fear: A Stolen Homeland is her most personal work to date, an homage to the enduring spirit of her father and a call to never forget the true cost of freedom.

Media Contact
Company Name: Literary Titan
Contact Person: Anna Unger Goodwin
Email: Send Email
Country: United States
Website: https://amzn.to/4neEx5g

Follicular Lymphoma Pipeline 2025: Mechanism of Action, Route of Administration, and Clinical Trial Insights Explored by DelveInsights | AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Follicular Lymphoma pipeline constitutes 45+ key companies continuously working towards developing 50+ Follicular Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Follicular Lymphoma Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Follicular Lymphoma Market.

The Follicular Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Follicular Lymphoma Pipeline Report:

Companies across the globe are diligently working toward developing novel Follicular Lymphoma treatment therapies with a considerable amount of success over the years.
Follicular Lymphoma companies working in the treatment market are InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharmaceuticals, ADC Therapeutics, AstraZeneca, Dr Reddy’s Laboratories, MAB WORKS, and others, are developing therapies for the Follicular Lymphoma treatment

Emerging Follicular Lymphoma therapies in the different phases of clinical trials are- ICP 248, ALLO-501, HMPL-689, PSB 202, Abexinostat, Loncastuximab tesirine, Acalabrutinib, DRL_RI, MIL62, and others are expected to have a significant impact on the Follicular Lymphoma market in the coming years.
In June 2025, The FDA has approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide (Revlimid) and rituximab (Rituxan) for treating patients with relapsed or refractory follicular lymphoma, as announced by the agency. This approval is based on findings from the phase 3 inMIND trial (NCT04680052), a double-blind, placebo-controlled study. In the trial, 548 patients with relapsed or refractory follicular lymphoma were randomly assigned to receive either the newly approved combination or a placebo along with lenalidomide and rituximab.
In March 2025, The European Commission (EC) has granted approval for lisocabtagene maraleucel (liso-cel; Breyanzi), a CD19-targeting CAR T-cell therapy, for use in adult patients with relapsed or refractory follicular lymphoma who have undergone at least two prior lines of systemic treatment, according to a press release by Bristol Myers Squibb.
In February 2025, Genmab A/S (Nasdaq: GMAB) has announced that Japan’s Ministry of Health, Labour and Welfare has granted approval for EPKINLY® (epcoritamab) to treat relapsed or refractory (R/R) follicular lymphoma (FL; Grades 1 to 3A) in patients who have received at least two previous lines of therapy. With this expanded approval, EPKINLY becomes the first and only subcutaneous T-cell engaging bispecific antibody authorized in Japan for use in both R/R FL and R/R large B-cell lymphomas—including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma—after two or more prior treatments.
In December 2024, At the 2024 American Society of Hematology (ASH) Annual Meeting, AstraZeneca presented interim results from a first-in-human trial investigating AZD0486, an innovative bispecific T-cell engager (BiTE), in patients with relapsed or refractory follicular lymphoma (r/r FL).
In August 2024, The company intends to file a supplemental Biologics License Application (sBLA) for tafasitamab by the end of 2024 to treat patients with follicular lymphoma (FL) who have not responded to at least one prior systemic anti-CD20 immunotherapy or chemo-immunotherapy, based on favorable Phase III trial outcomes.
In June 2024, A consortium headed by Eugene Private Equity and Korea Development Bank Private Equity has revealed its intention to acquire an 80% ownership stake in South Korean vaccine producer Boryung Biopharma Co. for 320 billion won (around USD 231 million).

Follicular Lymphoma Overview

Follicular lymphoma is a slow-growing (indolent) type of non-Hodgkin lymphoma that originates in B cells, a type of white blood cell. It typically develops in the lymph nodes but can also affect the bone marrow and spleen. Common symptoms include painless swollen lymph nodes, fatigue, and night sweats. Though not usually curable, it can be managed for years with treatments such as immunotherapy, chemotherapy, or targeted therapies.

Get a Free Sample PDF Report to know more about Follicular Lymphoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight

Emerging Follicular Lymphoma Drugs Under Different Phases of Clinical Development Include:

ICP 248: InnoCare Pharma
ALLO-501: Allogene Therapeutics
HMPL-689: HUTCHMED
PSB 202: Sound Biologics
Abexinostat: Xynomic Pharmaceuticals
Loncastuximab tesirine: ADC Therapeutics
Acalabrutinib: AstraZeneca
DRL_RI: Dr Reddy’s Laboratories
MIL62: MAB WORKS

Follicular Lymphoma Route of Administration

Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Follicular Lymphoma Molecule Type

Follicular Lymphoma Products have been categorized under various Molecule types, such as

Oligonucleotide
Peptide
Small molecule

Follicular Lymphoma Pipeline Therapeutics Assessment

Follicular Lymphoma Assessment by Product Type
Follicular Lymphoma By Stage and Product Type
Follicular Lymphoma Assessment by Route of Administration
Follicular Lymphoma By Stage and Route of Administration
Follicular Lymphoma Assessment by Molecule Type
Follicular Lymphoma by Stage and Molecule Type

DelveInsight’s Follicular Lymphoma Report covers around 50+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Follicular Lymphoma product details are provided in the report. Download the Follicular Lymphoma pipeline report to learn more about the emerging Follicular Lymphoma therapies

Some of the key companies in the Follicular Lymphoma Therapeutics Market include:

Key companies developing therapies for Follicular Lymphoma are – Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, ADC Therapeutics, Incyte Corporation, MorphoSys, AbbVie, Janssen Research & Development, Regeneron Pharmaceuticals, Novartis, MEI Pharma, BeiGene, Xynomic Pharmaceuticals, Bristol Myers Squibb, and others.

Follicular Lymphoma Pipeline Analysis:

The Follicular Lymphoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Follicular Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Follicular Lymphoma Treatment.
Follicular Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Follicular Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Follicular Lymphoma market.

Download Sample PDF Report to know more about Follicular Lymphoma drugs and therapies

Follicular Lymphoma Pipeline Market Drivers

Increase in prevalence of Follicular Lymphoma, emergence of effective novel therapies, increased Research and Developmental Activities are some of the important factors that are fueling the Follicular Lymphoma Market.

Follicular Lymphoma Pipeline Market Barriers

However, lack Of Cost-Effective Treatment, progression of disease within 2 years (POD24) in the Disease and other factors are creating obstacles in the Follicular Lymphoma Market growth.

Scope of Follicular Lymphoma Pipeline Drug Insight

Coverage: Global
Key Follicular Lymphoma Companies: InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharmaceuticals, ADC Therapeutics, AstraZeneca, Dr Reddy’s Laboratories, MAB WORKS, and others
Key Follicular Lymphoma Therapies: ICP 248, ALLO-501, HMPL-689, PSB 202, Abexinostat, Loncastuximab tesirine, Acalabrutinib, DRL_RI, MIL62, and others
Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies
Follicular Lymphoma Market Dynamics: Follicular Lymphoma market drivers and Follicular Lymphoma market barriers

Request for Sample PDF Report for Follicular Lymphoma Pipeline Assessment and clinical trials

Table of Contents

1. Follicular Lymphoma Report Introduction

2. Follicular Lymphoma Executive Summary

3. Follicular Lymphoma Overview

4. Follicular Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. Follicular Lymphoma Pipeline Therapeutics

6. Follicular Lymphoma Late Stage Products (Phase II/III)

7. Follicular Lymphoma Mid Stage Products (Phase II)

8. Follicular Lymphoma Early Stage Products (Phase I)

9. Follicular Lymphoma Preclinical Stage Products

10. Follicular Lymphoma Therapeutics Assessment

11. Follicular Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Follicular Lymphoma Key Companies

14. Follicular Lymphoma Key Products

15. Follicular Lymphoma Unmet Needs

16 . Follicular Lymphoma Market Drivers and Barriers

17. Follicular Lymphoma Future Perspectives and Conclusion

18. Follicular Lymphoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Follicular Lymphoma Pipeline 2025: Mechanism of Action, Route of Administration, and Clinical Trial Insights Explored by DelveInsights | AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED

Lee Partners Law Launches to Fight for Injured Workers Using Insider Defense Knowledge

Lee Partners Law: Injury Attorneys LLP brings a family-owned, client-first approach backed by decades of inside insurance defense experience.

A new California law firm is opening its doors with a bold mission: to protect injured workers using the same insider strategies once used against them. Lee Partners Law: Injury Attorneys LLP, founded by brothers David A. Lee and Michael Lee, launches today with a statewide focus on workers’ compensation cases—and a deep commitment to fighting for working families.

What sets the firm apart is the background of its founders. Both attorneys spent over two decades combined defending insurance companies and major employers. Now, the brothers are putting that knowledge to use on the other side—helping injured workers navigate a system that’s often confusing, unfair, and stacked against them.

“We’re brothers, business partners, and former defense attorneys who’ve sat inside insurance war rooms,” said David Lee, Founding Attorney. “We know exactly how those companies try to reduce or deny claims. And now we’re using everything we learned to protect the people they overlook—injured workers.”

Headquartered in Los Angeles and serving all of California, Lee Partners Law is a family-run practice built on trust, integrity, and aggressive legal representation. The firm’s focus is 100% workers’ compensation law, handling everything from denied claims and delayed treatment to serious injuries and maximum-value settlements.

The Lees say their approach combines hard-hitting strategy with personalized, compassionate service—something they believe only a small, family-led firm can provide.

“We’re not a giant corporate office. We’re two brothers who grew up together, work side by side, and care deeply about every client who walks through our doors,” added Michael Lee, Partner. “This firm is personal to us—and that makes us fight even harder.”

Lee Partners Law is proud to represent the workers who keep cities running. These are the people who power California every day, and they deserve someone in their corner when they get hurt on the job.

For more information or to schedule a free case evaluation, visit: https://www.leeinjuryattorneys.com

Media Contact
Company Name: Lee Partners Law: Work Injury Attorneys
Contact Person: David A Lee
Email: Send Email
Phone: 3102950822
Address:PO Box 3869
City: Valley Village
State: CA 91617
Country: United States
Website: https://www.leeinjuryattorneys.com

Top Real Estate Listing Agent in La Canada Flintridge, CA, Honored as Top Producer at Annual Company Awards Ceremony

La Canada Flintridge, CA – Professional excellence and consistent performance were recognized at a recent annual company awards ceremony, where outstanding achievement in real estate sales was celebrated among industry peers. The recognition highlights the importance of local market expertise, client dedication, and proven results in today’s competitive real estate environment.

Omar Bardumyan, a well-known real estate listing agent in La Canada Flintridge, CA, was honored as one of the company’s top producers at this prestigious ceremony. With over 15 years of experience since obtaining his license in 2008, Bardumyan has built a reputation for exceptional service and comprehensive market knowledge that consistently delivers results for his clients.

Having lived in the Foothills throughout his entire life, Bardumyan brings unparalleled local insights to his role as a La Canada Flintridge, CA Realtor. This deep-rooted connection to the community, combined with his extensive knowledge of the Los Angeles real estate market, positions him uniquely to understand both neighborhood nuances and broader market trends affecting property values and buyer preferences.

The current market environment presents both challenges and opportunities as interest rates continue to change and demand patterns shift across different property segments. As an experienced Realtor in La Canada Flintridge, CA, Bardumyan has adapted his approach to meet evolving client expectations, recognizing that today’s buyers and sellers seek faster responses, greater convenience, and more precise communication throughout their transactions.

“Clients want things more quickly today, and they’re looking for convenience,” explains Bardumyan. “You have to be precise, to the point, and make things convenient for them. Experience, local market knowledge, reputation, and communication skills are what really matter when clients are choosing their service provider.”

Market knowledge remains one of the most overlooked factors by clients when selecting representation, yet it proves critical to successful outcomes. For expert guidance from a top real estate agent in La Canada Flintridge, CA who combines local expertise with top-producer performance, contact Omar Bardumyan at https://www.laareahomes.com/ to begin your real estate journey with confidence.

Media Contact
Company Name: Omar Bardumyan | Real Estate Agent in La Cañada CA
Email: Send Email
Phone: +1 818 600 1787
Address:848 Foothill Blvd.
City: La Cañada Flintridge
State: California
Country: United States
Website: https://omarbardumyan.kw.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Listing Agent in La Canada Flintridge, CA, Honored as Top Producer at Annual Company Awards Ceremony

Real Estate Listing Agent in San Diego, CA, Sees Growing Demand from Bay Area Clients Seeking Statewide Market Expertise

San Diego, CA – A notable trend has emerged in California’s real estate market as professionals with comprehensive statewide expertise attract clients from distant regions seeking specialized knowledge across multiple markets. This cross-regional demand reflects the increasing complexity of California real estate transactions and the value clients place on working with experienced professionals who understand diverse market dynamics throughout the state.

Karim Abdulla has established himself as a leading real estate listing agent in San Diego, CA by developing expertise that extends far beyond local market boundaries. His business evolution from multifamily apartment complex investments to luxury home sales has provided him with deep insights into various property types and market segments, enabling him to serve clients with diverse real estate needs across California.

The ability to navigate different regional markets has become increasingly valuable as clients seek professionals who understand varying market conditions. As a San Diego, CA Realtor, Abdulla recently demonstrated this expertise by successfully closing on an East Bay home purchase for a client with a young family, applying techniques specifically tailored to Northern California market dynamics that differ significantly from Southern California approaches.

Client satisfaction remains the cornerstone of Abdulla’s approach, distinguishing him in a competitive industry. His commitment as a Realtor in San Diego, CA extends beyond simple transactions to building lasting relationships founded on trust and integrity. “Our real estate business stands out from the competition by prioritizing integrity above all else,” explains Abdulla. “We always ensure that our clients’ needs are met, even if it means going the extra mile to provide exceptional service.”

The comprehensive service model includes a full team of experienced stagers, appraisers, and photographers, ensuring every aspect of the buying or selling process receives professional attention. This integrated approach allows clients to experience seamless transactions while working with a single point of contact who maintains fiduciary responsibility throughout the process.

For clients seeking a dedicated real estate agent in San Diego, CA with proven statewide expertise and unwavering commitment to excellence, Karim Abdulla offers the experience and integrity needed to achieve real estate goals. Visit http://www.kaaproperties.com/ to begin your real estate journey with a professional who puts your success first.

Media Contact
Company Name: Karim Abdulla | Real Estate Agent in San Diego CA
Contact Person: Karim Abdulla
Email: Send Email
Phone: +1 619-813-5809
Address:16769 Bernardo Center Dr K28
City: San Diego
State: California 92128
Country: United States
Website: http://www.kaaproperties.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Real Estate Listing Agent in San Diego, CA, Sees Growing Demand from Bay Area Clients Seeking Statewide Market Expertise

FAA Policy and Global Demand Are Creating New Lift for Drone-Focused Stocks (ZENA, ONDS, UAVS, DPRO)

The commercial drone industry is on the verge of major expansion. Once limited to hobbyists and specialized pilots, unmanned aerial systems are becoming essential tools across agriculture, defense, construction, logistics, and public safety. According to Fortune Business Insights, the global commercial drone market is expected to grow from $10.2 billion in 2023 to more than $35 billion by 2030, driven by regulatory approvals, advances in automation, and wider adoption by enterprise and government users.

In the United States, the FAA is preparing to finalize Part 108, a long-anticipated rule enabling Beyond Visual Line of Sight (BVLOS) drone operations. This change could remove one of the largest barriers to scale, allowing drones to operate more like infrastructure and less like line-of-sight tools. Meanwhile, geopolitical tensions and national security concerns are accelerating investment in domestic drone capabilities, with the U.S. and its allies prioritizing sovereign manufacturing and defense-grade platforms.

As regulation catches up with technology and investment picks up, the drone sector is entering a new era of utility and scale. Here are a few stocks worth watching in this evolving market.

ZenaTech (Nasdaq: ZENA) is emerging as a first mover in converting legacy land survey and field service operations into efficient, scalable platforms powered by autonomous drones and a Drone as a Service (DaaS) model. The company’s strategy centers on acquiring traditional service providers—such as surveying firms, inspection vendors, and environmental contractors—and transforming them into subscription-based drone operations. These bolt-on acquisitions give ZenaTech direct access to customers and revenue while replacing outdated manual workflows with high-efficiency aerial services.

In the first quarter of 2025, ZenaTech reported $1.13 million in revenue, a 92 percent year-over-year increase, driven by both organic growth and the acquisitions of Oregon-based Weddle Surveying and Florida’s KJM Land Surveying. In May, the company moved to acquire a third Florida land survey firm, which would bring its national footprint to five survey operations. Each acquisition accelerates recurring revenue and expands ZenaTech’s customer base across regional markets.

Through its DaaS model, ZenaTech provides commercial and government customers with access to advanced drone services without the need for capital investments, pilot training, or regulatory approvals. Using the ZenaDrone 1000 and IQ Series platforms, clients receive thermal imaging, LiDAR, GPS mapping, and automated analytics that can complete inspections and surveys in hours instead of weeks. This data-rich model drives faster decision-making across construction, energy, real estate, agriculture, and public sector operations.

Policy is becoming a tailwind. The June 6 White House executive order fast-tracked FAA approvals for beyond visual line of sight drone missions and elevated procurement of U.S.-made drones in both commercial and defense markets. ZenaTech is working toward Green and Blue UAS certifications to fully access these expanding federal opportunities and position itself as a key provider of secure, NDAA-compliant drone systems.

While land surveying has been the initial focus, ZenaTech’s approach is highly replicable. The company is actively expanding into additional verticals like powerline inspection, industrial maintenance, security monitoring, and even wildfire forecasting. Its Clear Sky initiative in the Western U.S. uses AI and quantum computing to model environmental risks using drone swarms, demonstrating the platform’s adaptability and long-term value creation.

With over 20 acquisition targets in its pipeline and a clear national strategy to modernize field operations across sectors, ZenaTech represents a differentiated play on the future of drone-powered infrastructure. For investors seeking exposure to recurring-revenue platforms in underserved industrial markets, ZENA offers a compelling opportunity.

Ondas Holdings (NASDAQ: ONDS) is emerging as a key player in the transformation of government and commercial operations through autonomous drone innovation. Its Ondas Autonomous Systems unit, comprising American Robotics and Airobotics, is actively replacing legacy infrastructure and surveillance workflows with advanced drone platforms built for round-the-clock deployment and remote operations.

The Optimus System, the first FAA-certified small UAS for autonomous security and data capture, recently secured a $14.3 million order from a major defense customer, marking the largest single purchase in the company’s history. That deal, alongside new contracts across Europe and the Middle East, has helped push Ondas’ drone revenue backlog to $28.7 million, up sharply from $10 million at the start of 2025. As of Q1, the company reported $4.2 million in revenue, driven almost entirely by its drone business, and reaffirmed a full-year revenue outlook of at least $25 million.

Ondas is also gaining momentum with its Iron Drone Raider counter-UAS platform and the newly adopted Kestrel drone detection system, which was recently selected by a major US urban public safety agency. These platforms have demonstrated strong traction across military, homeland security, and critical infrastructure markets.

The company’s regulatory head start is a competitive advantage. Ondas was the first to receive FAA approval for autonomous BVLOS operations without on-site personnel, opening the door to scalable drone deployments across sensitive, high-value applications. As the FAA accelerates its move toward broader BVLOS rulemaking, ONDS stands positioned to capitalize.

With a growing global footprint, strategic partnerships with firms like Palantir and Volatus, and expanding adoption across defense and public safety sectors, Ondas offers leveraged exposure to the rise of fully autonomous aerial systems in mission-critical environments.

Draganfly Inc. (NASDAQ: DPRO) is carving out a strategic niche as a North American drone manufacturer with deep defense and public safety traction. With over 25 years of experience in unmanned systems, Draganfly is positioned to benefit from rising demand for modular, mission-adaptable drone platforms in high-stakes environments.

Recent U.S. and Canadian defense developments have placed the company at the forefront of procurement pipelines. Draganfly’s Flex FPV system, designed for rapid deployment and multi-role functionality, has begun deliveries to a major U.S. prime contractor supporting land systems operations for allied forces. With speeds over 149 kilometers per hour and the ability to carry payloads up to 10 pounds, the platform’s modular design allows field teams to adapt it on the fly to tactical, reconnaissance, or training missions. The system’s operational validation stems from combat zone deployments and extensive testing with defense customers.

At the Global Drone Innovation and Defense Coalition Summit in Latvia, Draganfly was the only provider showcasing a fully modular FPV system and a portfolio of interoperable tactical platforms. This presence reinforced the company’s leadership in allied drone development.

Further momentum is building through its selection by the Cochise County Sheriff’s Department for a border-focused drone pilot program under the U.S. Executive Order on drone dominance. This positions Draganfly to expand into homeland surveillance and smart law enforcement.

Canada’s newly announced $80 billion defense modernization initiative also includes funding for unmanned systems. Draganfly has already integrated Department of National Defence-specified communications systems into its Commander and Apex platforms, aligning with national security priorities and procurement requirements. These integrations, combined with strong operational validation like the 100 percent success rate at SMEX25 with the U.S. Army, underscore DPRO’s upside as a secure, adaptable drone provider in a rapidly scaling sector.

AgEagle Aerial Systems (NYSE: UAVS) is emerging as a quietly strategic play in the global drone ecosystem, benefiting from regulatory tailwinds, cross-border partnerships, and improved financial execution. In June, the company was once again invited to a White House policy roundtable to advise on FAA Rule Part 108, which is expected to formally authorize Beyond Visual Line of Sight (BVLOS) drone operations. The pending rule represents a generational inflection point for commercial drone usage in agriculture, construction, energy, and emergency response. AgEagle’s inclusion in these sessions signals its positioning as a key stakeholder in defining future drone policy and infrastructure.

While it influences policy in Washington, the company is also scaling its international footprint. In May, AgEagle announced a strategic alliance with India-based Vyom Drones to manufacture and distribute its eBee X drone system across India’s fast-growing agriculture sector. With India’s agri-drone market projected to surpass $600 million by 2030, this agreement gives AgEagle first-mover advantage in a market with 345 million acres of arable land and increasing federal support for precision farming.

Financially, the company’s Q1 2025 report showed meaningful progress. Net income swung to a $7 million profit versus a $6.3 million loss a year earlier. Gross margins improved to 58.5%, and drone sales nearly doubled. A focused reduction in operating expenses and a streamlined product strategy appear to be paying off.

In parallel, AgEagle is expanding sensor integrations through new collaborations, such as a partnership with Ascent AeroSystems to pair its RedEdge-P camera with the rugged Spirit UAV platform. The company’s ability to remain lean while diversifying revenue channels in policy, hardware, and software makes it a differentiated, small-cap drone stock positioned to benefit from domestic and international catalysts.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ZenaTech Ltd. to assist in the production and distribution of content related to ZENA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: FAA Policy and Global Demand Are Creating New Lift for Drone-Focused Stocks (ZENA, ONDS, UAVS, DPRO)

SAGA Metals Is A Critical Minerals Investment Proposition Hiding in Plain Sight

The market isn’t just underestimating SAGA Metals Corp. (TSX-V: SAGA | OTCQB: SAGMF | FSE: 20H)—it’s outright missing it. At a time when governments are scrambling to secure supply chains for lithium, uranium, vanadium, titanium, and iron, SAGA is sitting on a cross-commodity portfolio that looks tailor-made for the energy transition economy.

Moreover, while most juniors are still chasing capital to test ideas, SAGA already has assets in motion, data in hand, and major mining players at the table. Know this as well— SAGMF isn’t presenting a single-character story about one project or one commodity. The theme is about positioning. Because SAGA isn’t working and hoping to be relevant in five years—it’s designed to matter now. And at its current $0.19 a share, the value proposition for this low-volume segment player looks ripe for appreciation. Here’s why:

A Portfolio That Checks Every Box

SAGA controls four 100%-owned properties spanning over 125,000 hectares across Quebec and Labrador, which are among the world’s top-ranked mining jurisdictions. Each project targets a critical mineral with explicit global demand and strategic significance.

At the top of the list is SAGA’s Legacy Lithium Project in James Bay, Quebec—a region now defined by blockbuster discoveries and billion-dollar takeouts. But SAGA doesn’t just own land in this district. It owns land optioned to Rio Tinto (NYSE: RIO), one of the world’s largest mining companies. Under the terms of their agreement, Rio can earn 75% of the Legacy Project by spending C$44.4 million—meaning SAGA retains a 25% interest in a de-risked, potentially world-class lithium resource.

The neighboring Amirault Lithium Project, acquired from geologist Jody Dahrouge—the same talent behind Patriot Battery Metals’ (OTCQX: PMETF) CV5 lithium discovery—adds even more firepower. Together, these properties form a commanding land package directly along the land trend from Rio’s Galinée, Winsome Resources’ Adina, and Azimut’s lithium targets. Pegmatite outcrops have already been mapped across both properties, with fieldwork underway to define drill targets for 2025.

But lithium is only one leg of SAGMF’s growth engine.

Uranium with Regional Gravity

In Labrador, SAGA’s Double Mer Uranium Project is emerging as one of the most compelling early-stage uranium stories in Canada. Spanning an 18-kilometer trend with uranium-rich pegmatites at the surface, the project has delivered scintillometer readings as high as 27,000 CPS—surpassing historical benchmarks—and rock samples up to 0.428% U₃O₈.

Importantly, this isn’t just a numbers game. SAGA is advancing a systematic drill strategy, starting with the Luivik Zone. The intention isn’t to chase flashy intercepts but to prove large-scale tonnage across a consistent grade profile. That puts Double Mer directly on par with the Central Mineral Belt to the north, home to uranium players like Paladin Energy (OTCQX: PALAF) and Atha Energy (OTCQX: SASKF). If SAGA can replicate even a fraction of those resources, the upside for shareholders could be exponential.

SAGA Is On The Radar

Then there’s Radar—SAGMF’s titanium-vanadium-iron project in Labrador that’s been quietly building momentum, and now has the technical firepower to match. On June 4, 2025, SAGA announced the appointment of Paul McGuigan, P.Geo., as a Qualified Person to oversee the Radar Ti-V-Fe Project.

That’s not a ceremonial title. McGuigan brings over 50 years of international experience across layered mafic intrusions, Fe-Ti-V deposits, and advanced metallurgical QAQC. He has led feasibility-level projects, managed drill programs on similar intrusions, and even co-founded a laboratory focused on critical mineral separation techniques.

This appointment comes as SAGA confirmed the results of its 2025 winter drill program—results that move Radar firmly into the category of being a serious development asset. Highlights include:

20.2 meters grading 31.35% Fe, 6.32% TiO₂, and 0.435% V₂O₅
57.7 meters grading 27.09% Fe, 5.31% TiO₂, and 0.365% V₂O₅
50 meters grading 24.49% Fe, 4.74% TiO₂, and 0.305% V₂O₅

Additional intercepts confirmed that vanadiferous titanomagnetite-rich zones average between 20% and 40% titanomagnetite, with localized concentrations exceeding 60%. These are the kinds of grades that rival multi-billion-dollar projects across the border in Quebec.

Even more critical is the message geology is telling: the oxide layering persists to vertical depths of 300 meters, and SAGA’s 2024–2025 fieldwork has validated that historical airborne magnetic anomalies align tightly with mineralized zones. That means the tools to expand are working, and the system appears to hold scale far beyond the initial 1/40th tested.

Best said, Radar isn’t a blue-sky dream anymore. It’s real. And with McGuigan onboard, it now has a proven architect.

Why SAGA Metals Now?

SAGA doesn’t need hype. It has substance. The company is strategically positioned at the intersection of macro-critical supply chains and geologically compelling terrain. With meaningful ownership, near-term exploration activity, and a clean capital structure, SAGA Metals offers a rare opportunity for upside in a sector dominated by early-stage noise.

It also plays very well to investors seeking exposure to lithium, uranium, vanadium, and iron, backed by a major partner and operating in Tier 1 jurisdictions. By all measures, that’s an excellent setup.

Furthermore, SAGMF’s potential is now being further sharpened by the appointment of Paul McGuigan, whose five decades of geological and metallurgical experience are being directly applied to unlocking Radar’s full scope. With assays from the 2025 winter drill program now in hand, SAGA has already confirmed zones of high-grade vanadiferous titanomagnetite, continuity of mineralization to 300 meters, and the reliability of its airborne magnetic survey data. This is not an exploration theory—it’s a confirmed, de-risked mineral system in an infrastructure-rich region.

In other words, SAGA’s projects are not purely conceptual—they’re drill-tested, partner-backed, and professionally managed. And with multiple active campaigns unfolding across commodity assets, SAGA Metals (OTCQB: SAGMF) isn’t just exploring the future of energy—it’s positioned to help build it.

Sources and references:

https://sagametals.com/projects/
https://sagametals.com/saga-metals-and-rio-tinto-sign-option-to-joint-venture-agreement-for-lithium-asset-in-eastern-james-bay-quebec/
https://sagametals.com/investment-highlights/
https://sagametals.com/corporate-presentation/
https://finance.yahoo.com/quote/SAGMF/history/

Disclaimer and disclosures: This Disclaimer and Disclosure statement is a permanent part of this content. Any reproduction of this content that does not include the Disclaimer and Disclosure statement is unauthorized and strictly prohibited. All investments are subject to risk, which must be considered on an individual basis before making any investment decision. This paid advertisement includes a stock profile of SAGA Metals Corp. This paid advertisement is intended solely for information and educational purposes and is not to be construed under any circumstances as an offer to sell or a solicitation of an offer to purchase any securities. In an effort to enhance public awareness, Hawk Point Media Group, LLC, was hired by Shore Thing Media Group, LLC, to create and distribute digital content for SAGA Metals Corp.. Shore Thing Media Group, LLC. compensated Hawk Point Media Group, LLC. USD five-thousand-dollars via wire transfer to complete and distribute these services. This advertisement will be disseminated for a period of one month, beginning on June 24, 2025, and ending on July 23, 2025. Hawk Point Media Group, LLC. owners, officers, principals, affiliates, contributors, and/or related parties do not own, intend to own, sell, or intend to sell SAGA Metals Corp. stock. However, it is prudent to expect that those hiring Hawk Point Media Group, LLC, including that company’s owners, employees, and affiliates, may sell some or even all of the SAGA Metals Corp. shares that they own, if any, during and/or after this engagement period. If successful, this advertisement will increase investor and market awareness of SAGA Metals Corp. and its securities, which may result in an increased number of shareholders owning and trading the securities, increased trading volume, and possibly an increase in share price, which may be temporary. This advertisement does not purport to provide a complete analysis of SAGA Metals Corp. or its financial position. The agency providing this content is not, and does not purport to be, a broker-dealer or registered investment advisor. This advertisement is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a registered broker-dealer or registered investment advisor or, at a minimum, doing your own research if you do not utilize an investment professional to make decisions on what securities to buy and sell, and only after reviewing the financial statements and other pertinent publicly-available information about SAGA Metals Corp. Further, readers are specifically urged to read and carefully consider the Risk Factors identified and discussed in SAGA Metals Corp. SEC filings. Investing in microcap securities such as SAGA Metals Corp. is speculative and carries a high degree of risk. Past performance does not guarantee future results. This advertisement is based exclusively on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, Hawk Point Media Group, LLC. cannot guarantee the accuracy or completeness of the information and are not responsible for any errors or omissions. This advertisement contains forward-looking statements, including statements regarding expected continual growth of SAGA Metals Corp. and/or its industry. Hawk Point Media Group, LLC. note that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect SAGA Metals Corp. actual results of operations. Factors that could cause actual results to vary include the size and growth of the market for SAGA Metals Corp.’s products and/or services, the company’s ability to fund its capital requirements in the near term and long term, federal and state regulatory issues, pricing pressures, and other factors. All trademarks used in this advertisement are the property of their respective trademark holders, and no endorsement by such owners of the contents of this advertisement is made or implied. Hawk Point Media Group, LLC, is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made to any rights in any third-party trademarks.

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SAGA Metals Is A Critical Minerals Investment Proposition Hiding in Plain Sight